<DOC>
	<DOCNO>NCT01190436</DOCNO>
	<brief_summary>The aim 12-week , multicenter , interventional , prospective , open-label single-arm study evaluate safety efficacy 5 milligram per day ( mg/day ) 10 mg/day bisoprolol Filipino hypertensive subject diabetes monotherapy add-on therapy .</brief_summary>
	<brief_title>A 12-week , Multicentric Study Evaluate Safety Efficacy Bisoprolol Filipino Hypertensive Subjects With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Adult subject hypertension , either newly diagnose treat currently uncontrolled define Joint National Committee ( JNC ) 7 subject Type 2 diabetes mellitus ( T2DM ) ( , great equal [ &gt; = ] 130/80 mmHg ) Aged least 18 year old Diagnosed T2DM already antidiabetic therapy , glycosylated hemoglobin le 7 percent Subjects already betablocker therapy time recruitment Subjects heart rate 60 beat per minute ( bpm ) rest Subjects secondary hypertension , congenital heart disease , coronary artery disease , peripheral arterial disease congestive heart failure stage Subjects coronary conduction disorder ( bundle branch block ) Subjects sign definitive target organ damage consistent World Health Organization ( WHO ) Stage III severe renal hepatic disease Subjects pregnant expect pregnant within 24week study period Subjects oral contraceptive Subjects asthma history asthma Subjects document severe renal disease Subjects antineoplastic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Bisoprolol</keyword>
</DOC>